Recent Press Releases

Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury

04/12/17 - Investigating New Patient Cohort with Cervical Injury GERMANTOWN, Md., April 12, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based o... More

Neuralstem Reports Year End 2016 Fiscal Results and Business Update

03/23/17 - Expects to Report NSI-189 Phase 2 major depressive disorder study results in Q3 ahead of schedule GERMANTOWN, Md., March 23, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the dev... More

Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21

03/17/17 - GERMANTOWN, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announces that Rich ... More
More

Upcoming Events


There are currently no events scheduled.
More
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
Share PageShare Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet